Cell>Point Executes Asia Pacific License with HYUN IMC for Cancer and Heart Disease Diagnostic Imaging Agent …

CENTENNIAL, Colo.--(BUSINESS WIRE)--

Cell>Point today announced that it had entered into a licensing agreement for the countries of South Korea, Taiwan, Malaysia, Vietnam, and the Philippines with HYUN IMC Co., Ltd., headquartered in Seoul, South Korea.

The license agreement covers the kit manufacture, marketing and distribution of Cell>Points cancer and cardiology imaging product based on its EthylenediCysteine-n-acetyl-Glucosamine (EC-G) technology platform. Specifically, the product is technetium-99m-labeled EC-G (99mTc-EC-G). In addition, HYUN IMC will be responsible for sponsoring clinical studies and seeking regulatory approval in each of the countries covered by the license.

Cell>Point will receive an upfront payment, and development and regulatory milestone payments, as well as royalties on gross sales from HYUN IMC.

We are confident that HYUN IMC will be an excellent partner that will affiliate with one of the leading Korean pharmaceutical companies to assist in the marketing of 99mTc-EC-G, said Greg Colip, Cell>Point CEO.

The five Asia Pacific countries comprise approximately 296 million people, according to the CIA World Factbook.

The company has already completed a Brazil license for the product, reaching Brazils 206 million citizens and the second fastest-growing market globally, behind only China, according to healthcare industry information provider IMS Health.

99mTc-EC-G, invented at The University of Texas MD Anderson Cancer Center and acquired by Cell>Point, is a target-specific molecular imaging radiopharmaceutical that has moved into a Phase 3 lung cancer imaging trial and Phase 2 cardiology imaging trial.

99mTc-EC-G is injected intravenously and then imaged using a Single Photon Emission Computed Tomography (SPECT) camera, sometimes referred to as a gamma camera. The current standard in cancer molecular imaging is fluorine-18 FluoroDeoxyGlucose (18F-FDG) imaged using a Positron Emission Tomography (PET) camera, which are rare.

99mTc-EC-G Phase 3 lung cancer imaging trial

Continued here:
Cell>Point Executes Asia Pacific License with HYUN IMC for Cancer and Heart Disease Diagnostic Imaging Agent ...